Literature DB >> 25175940

TET1 partially mediates HDAC inhibitor-induced suppression of breast cancer invasion.

Hou-Gen Lu1, Wang Zhan2, Lin Yan1, Rui-Ying Qin3, Yi-Peng Yan3, Zhen-Jiang Yang3, Gui-Chao Liu4, Gui-Qin Li3, Hai-Feng Wang5, Xing-Liang Li6, Zhi Li6, Lu Gao7, Guo-Qing Chen8.   

Abstract

Histone deacetylases (HDACs) are important in chromatin remodeling and epigenetic regulation of gene expression. Histone deacetylase inhibitors (HDACi) have highly effective anti-metastatic and anti-angiogenic activity in various types of cancer, while the molecular mechanisms involved in this process are not fully understood. In the present study, trichostatin A (TSA), a HDACi, was found to suppress MCF-7 breast carcinoma cell invasion and upregulate TET1 expression in a dose-dependent manner. TET1, a dioxygenase involved in cytosine demethylation, is downregulated during breast cancer progression. TET1 knockdown in MCF-7 cells facilitates cell invasion, inhibits the expression of tissue inhibitors of metalloproteinase 2/3 (TIMP2/3) and promotes matrix metalloproteinases (MMP) 2/9 transcriptional activity. Importantly, TET1 depletion impaired the inhibitory effect of TSA on breast cancer cell invasion. Together, these results illustrated a mechanism by which TET1 partially mediates HDACi elicited suppression of breast cancer invasion.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25175940     DOI: 10.3892/mmr.2014.2517

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  8 in total

1.  miR-29b is an indicator of prognosis in breast cancer patients.

Authors:  Yoshiaki Shinden; Tomohiro Iguchi; Sayuri Akiyoshi; Hiroki Ueo; Masami Ueda; Hidenari Hirata; Shotaro Sakimura; Ryutaro Uchi; Yuki Takano; Hidetoshi Eguchi; Keishi Sugimachi; Yuko Kijima; Shoji Natsugoe; Koshi Mimori
Journal:  Mol Clin Oncol       Date:  2015-05-12

2.  Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells.

Authors:  Matteo Forloni; Romi Gupta; Arvindhan Nagarajan; Li-Sha Sun; Yuying Dong; Valentina Pirazzoli; Maria Toki; Anna Wurtz; Mary Ann Melnick; Susumu Kobayashi; Robert J Homer; David L Rimm; Scott J Gettinger; Katerina Politi; Shaillay Kumar Dogra; Narendra Wajapeyee
Journal:  Cell Rep       Date:  2016-06-23       Impact factor: 9.423

Review 3.  Dissecting bipolar disorder complexity through epigenomic approach.

Authors:  B Ludwig; Y Dwivedi
Journal:  Mol Psychiatry       Date:  2016-08-02       Impact factor: 15.992

4.  The effect of sodium butyrate and cisplatin on expression of EMT markers.

Authors:  Alena Mrkvicova; Marcela Chmelarova; Eva Peterova; Radim Havelek; Ivana Baranova; Petra Kazimirova; Emil Rudolf; Martina Rezacova
Journal:  PLoS One       Date:  2019-01-17       Impact factor: 3.240

5.  Hydroxyurea promotes TET1 expression and induces apoptosis in osteosarcoma cells.

Authors:  Songsong Teng; Chunhui Ma; Yinxian Yu; Chengqing Yi
Journal:  Biosci Rep       Date:  2019-05-14       Impact factor: 3.840

6.  Downregulation of TET1 Promotes Bladder Cancer Cell Proliferation and Invasion by Reducing DNA Hydroxymethylation of AJAP1.

Authors:  Yi-Lin Yan; Zheng-Nan Huang; Zhen Zhu; Yang-Yan Cui; Mei-Qian Li; Rui-Min Huang; Jun Yan; Bing Shen
Journal:  Front Oncol       Date:  2020-05-21       Impact factor: 6.244

7.  TET1 exerts its anti-tumor functions via demethylating DACT2 and SFRP2 to antagonize Wnt/β-catenin signaling pathway in nasopharyngeal carcinoma cells.

Authors:  Jiangxia Fan; Yan Zhang; Junhao Mu; Xiaoqian He; Bianfei Shao; Dishu Zhou; Weiyan Peng; Jun Tang; Yu Jiang; Guosheng Ren; Tingxiu Xiang
Journal:  Clin Epigenetics       Date:  2018-08-03       Impact factor: 6.551

8.  Immunity drives TET1 regulation in cancer through NF-κB.

Authors:  Evelyne Collignon; Annalisa Canale; Clémence Al Wardi; Martin Bizet; Emilie Calonne; Sarah Dedeurwaerder; Soizic Garaud; Céline Naveaux; Whitney Barham; Andrew Wilson; Sophie Bouchat; Pascale Hubert; Carine Van Lint; Fiona Yull; Christos Sotiriou; Karen Willard-Gallo; Agnès Noel; François Fuks
Journal:  Sci Adv       Date:  2018-06-20       Impact factor: 14.136

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.